Follow us on:

Linkedin Facebook
Potential Treatment for COVID-19

Avacta Group Antigen distribution agreement and potential treatment for COVID-19 (Interview)

Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss a distribution agreement with Medusa 19 for its rapid antigen test direct to consumer. Alastair talks us through this latest news, provides an update on the development of the tests and provides details around the potential Affimer treatment for COVID 19.

Avacta Group’s Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal’s immune response, to generate new antibodies; poor specificity in many cases; large size and cost.

Find more news, interviews, share price & company profile here for:

Share this interview

Twitter
LinkedIn
Facebook
Email
WhatsApp
Potential Treatment for COVID-19
Avacta Group Antigen distribution agreement and potential treatment for COVID-19 (Interview)

Other Interviews

More News

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.